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W
hen Rachel Carson took 
on the task of defining 
environmental  health 
advocacy in the early 1960s, she made 
the business of government oversight look 
simple and straightforward. “Much of 
the necessary knowledge is now available, 
but we do not use it,” she wrote in her 
1962 book Silent Spring. “We train ecolo­
gists in our universities and even employ 
them in our government agencies, but 
we seldom take their advice. We allow 
the chemical death rain to fall as though 
there were no alternative, whereas in fact 
there are many, and our ingenuity could 
soon discover more if given opportunity.”
Carson would likely be dazzled by the 
extent to which governments of all stripes 
have since called on scientific experts to 
help populate a regulatory galaxy that 
extends from the humblest of municipal 
bailiwicks to the global economy. Never­
theless, the unfolding of this new world of 
prevention and protection has been neither 
tidy nor consistent. The scientific com­
munity generates volumes of data about 
potential hazards to human health, but 
the process of interpretation—resulting 
ultimately in the development of policy—
is often heavily shaped by political, eco­
nomic, and even cultural interests, which 
can vary dramatically from one hazard to 
the next, as well as from one jurisdiction 
to the next.
The outcome of any regulatory delib­
eration can therefore be unexpected and 
downright frustrating. A given agent 
might be labeled a toxic threat in one 
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place while being tolerated without preju­
dice somewhere else, even as the architects 
of each policy looked at the very same data. 
That prospect might puzzle many thought­
ful and earnest observers who believe defin­
itive scientific findings should yield equally 
definitive responses. 
Daniel Sarewitz recalls his early days as 
a Congressional Science Fellow in 1989. 
“The scales fell from my eyes after about a 
week of being [in Washington, DC],” he 
says. “When you’re a scientist working in 
academia, what you see is scientists arguing 
about difficult problems to try to arrive at 
the truth. When you’re on the Hill, you real­
ize what’s really going on is these problems 
are complicated both in terms of the science 
and in terms of the values. It’s possible to 
bring many different scientific lenses—inter­
pretations of data, choices of what data to 
use, what theories to use—to any given com­
plex problem. Not surprisingly, those choices 
end up mapping onto value preferences and 
political preferences.”
Today Sarewitz is director of the Con­
sortium for Science, Policy, & Outcomes, 
which, in its own words, seeks to enhance 
the capacity of public policy to link scientific 
research to beneficial societal outcomes. But 
Sarewitz says the consortium faces resistance 
in moving these perspectives into open public 
debate. The difficulty, as he outlined in an 
article in the October 2004 issue of Environ-
mental Science & Policy, stems from a com­
mon desire of both advocates and opponents 
of any given regulation to invoke science to 
make their respective cases. The former will 
insist that current knowledge warrants doing 
something, while the latter point to uncer­
tainties in that same knowledge as justifi­
cation for doing less, or perhaps nothing.
A Case in Point
The example of bisphenol A (BPA) has 
recently testified to the ever more intri­
cate subtleties of the regulatory review pro­
cess. This organic compound is a building 
block in a number of widely used poly­
mers, including the protective coating 
applied to the inside of food cans and the 
plastics used to form beverage containers 
such as baby bottles. Agencies in North 
America and Europe have regularly con­
sidered  the  potential  health  implications 
of this product ever since it entered com­
mercial  use  more  than  50  years  ago. 
Although  various  animal  models 
raised questions about specific hazards—
such as altering hormonal balances in 
rats—regulators generally concluded that 
any effect on humans was too small to yield 
measurable effects. Canada broke with inter­
national consensus in 2008, however, when 
it declared BPA toxic under its 1999 Cana­
dian Environment Protection Act (CEPA), 
which applies to activities of two key fed­
eral departments, Environment Canada and 
Health Canada. “We have concluded that 
early development is sensitive to the effects 
of bisphenol A,” stated Health Minister 
Tony Clement in his formal announcement 
of the government’s move. “Although our 
science tells us exposure levels to newborns 
and infants are below the levels that cause 
effects, it is better to be safe than sorry. 
And so, if no new, relevant, and compelling 
information comes forward during the pub­
lic consultation period, it is our intention to 
ban the importation, sale, and advertising 
of polycarbonate baby bottles.” 
Meanwhile, in 2006, the European 
Food Safety Authority (EFSA), an indepen­
dent risk assessment agency under the Euro­
pean Union, had conducted its own evalu­
ation of BPA and concluded that, for the 
general population, exposure to the chemi­
cal was well below the tolerable daily intake 
(TDI), or the highest dose that can be toler­
ated every day without adverse effects. This 
TDI was based on the findings of several 
toxicity studies in rats, which together had 
yielded a specific NOAEL (no­observed­
adverse­effect level, or the highest dose at 
which an adverse effect is not seen).
In July 2008, EFSA re­examined the 
safety of BPA, focusing on the possible dif­
ferences between neonates and adults (in 
both humans and rats) in eliminating BPA 
from the body. EFSA’s scientific panel con­
cluded that neonates are sufficiently capable 
of eliminating BPA from the body and that, 
because of metabolic differences, rats are 
more exposed to BPA than are humans. 
Shortly before Canada declared BPA toxic, 
EFSA made a public statement contending 
that the existing body of data on BPA did 
not warrant such action on its part.
The U.S. Food and Drug Administration 
(FDA), for its part, made specific reference 
to that EFSA observation and to a similar 
report from the Japanese National Institute 
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of Advanced Industrial Science and Technol­
ogy in reaching its own conclusions about 
the safety of BPA. “Each of these documents 
considered the question of a possible low­
dose effect and concluded that no current 
[human] health risk exists for BPA at the cur­
rent exposure level,” stated an agency release 
issued in spring 2008. The FDA declared 
BPA safe in a draft assessment released 
15 August 2008, but by October, a subcom­
mittee of the FDA Science Board issued a 
report challenging the agency’s conclusions, 
describing the assessment’s defined margin of 
safety as inadequate. 
Steven Hentges, whose perspective as a 
representative of the American Chemistry 
Council became part of the official record of 
an October 31 meeting of the board, rejects 
this characterization. “This definitive con­
clusion and other similar statements in the 
report do not appear to be based on a sound 
and thorough scientific analysis, and in par­
ticular, one that follows the subcommittee’s 
own recommendations,” he said.
What’s the Bottom Line?
The debate around BPA could look arcane 
to a parent who simply wants to know if 
baby’s bottle is at all harmful. For George 
Enei, acting director general of Environ­
ment Canada’s Science and Risk Assessment 
Directorate, the issue sits within a larger 
bureaucratic context. “Most people ask the 
question ‘How can a chemical substance be 
toxic in Canada but not in the United States 
or vice versa?’” he says. “The basic answer 
is that, while each country is following the 
same scientific methods and protocols, our 
respective legislation is different.”
Enei explains that whereas the Unit­
ed States combines various processes of 
environ  mental health assessment and man­
agement, Canada has separated them into 
three steps under CEPA. “We conduct a 
risk assessment that assembles all of the 
available science to determine if a substance 
is harmful or has the potential to cause 
harm to humans or the environment,” he 
says. “If the answer is yes, the substance is 
added to the list of toxic substances. Once 
the substance is on the list, we have access 
to a variety of options under CEPA to man­
age the risks that the assessment has identi­
fied. These include pollution prevention 
plans, regulations, or, in extreme cases, 
eliminating the substance from being used 
or brought into Canada.”
Enei credits Canada with taking these 
efforts further with its Chemicals Manage­
ment Plan, leading the international commu­
nity in a comprehensive sorting of no fewer 
than 23,000 chemicals that could pose some 
kind of threat to the environment or human 
health. Since the launch of this initiative in 
2006, the United States and European Union 
have followed suit with similar programs: 
the U.S. Environmental Protection Agency’s 
(EPA) Chemicals Assessment and Manage­
ment Program (ChAMP) and the European 
Commission’s Registration, Evaluation, 
Authorisation and Restriction of Chemical 
Substances (REACH) system. The three pro­
grams are equally ambitious, addressing tens 
of thousands of agents old and new. 
BPA had been among 200 chemicals 
singled out by the Chemicals Management 
Plan for inclusion in a “challenge to indus­
try,” meaning these chemicals were flagged as 
the most likely to cause environmental and/
or health problems, and their manufacturers 
would be among the first to be asked about 
how these substances were being handled. 
Also, under provisions of CEPA, screening 
assessments examine scientific information and 
develop conclusions by incorporating weight­
of­evidence and precautionary approaches. 
Barbara McElgunn, health policy officer 
with the Learning Disabilities Association of 
Canada, has been examining the scientific 
findings around BPA and developmental 
neurotoxicity for years. “This is the first 
time in my memory that Canada has really 
taken the lead on any chemical in terms 
of regulation,” she says, noting that all too 
often regulatory policies have lagged behind 
decisions already made in the United States.
That might also have happened with 
respect to BPA, she adds, but the Chem­
icals Management Plan appears to have 
added momentum to Canada’s work in this 
field. By setting a fresh agenda that tran­
scends the mandates of existing govern  ment 
departments, this new program managed 
to bring at least one longstanding debate to 
the fore. 
“The tipping point is public political 
concern,” McElgunn says. “When you raise 
public political concern, then it seems that 
regulators can take action. If there’s no 
public concern and only scientific concern, 
it’s a different kettle of fish, unfortunately.”
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Complexity and Competing Interests
In the view of Peter Andrée, a political 
scientist at Carleton University in Ottawa, 
government actors will incorporate other 
factors outside of scientific evidence into 
their decisions, regardless of how much 
respect they have for the pertinent science. 
In this way he explains discrepancies in 
bureaucratic attitudes toward recombinant 
bovine somatotropin (rbST, also known 
as recombinant bovine growth hormone, 
rbGH) a synthetic version of a protein pro­
duced in the pituitary glands of cattle that 
enhances milk output. 
The FDA sanctioned the use of rbST 
across the United States in 1993, while 
Health Canada eventually banned it in 
1999, despite the findings of an independent 
review panel that there was “no biologically 
plausible reason for concern about human 
safety if rbST were to be approved for sale in 
Canada.” That panel’s only proviso was an 
rbST oral toxicity study in rats that resulted 
in a single test animal developing an anti­
body response at low dosage. 
In its 1999 Report on the Food and Drug 
Administration’s Review of the Safety of Recom-
binant Bovine Somatotropin, the FDA wrote 
that “such response was consistent with that 
produced by a number of food proteins and is 
not necessarily an indication of absorption of 
intact rbGH. As rbGH produces significant 
biological effects when injected into rats, this 
study supported the inability of rbGH to 
cause significant biological effects following 
oral administration even at doses 50 times 
greater than the injected dose.” The FDA 
then suggested that “the Canadian reviewers 
did not interpret the study results correctly 
and that there are no new scientific con­
cerns regarding the safety of milk from cows 
treated with rbGH.”
For  his  part,  Andrée  regards  this 
exchange from a different perspective. “My 
tendency is to look first towards the politi­
cal economy of the issue,” he says. More 
specifically, he notes significant distinctions 
between each country’s dairy industry. The 
larger, corporation­centered U.S. pro  ducers 
would welcome the prospect of getting more 
milk from the same number of cows, he 
says. Sentiments tended the other way in 
Canada, where more of those producers are 
family­run operations.
“There’s a whole supply management 
system that keeps farm sizes reasonably small 
and allows them to be profitable,” explains 
Andrée, adding that these producers would 
be more likely to lobby the Canadian gov­
ernment to restrict rbST, thereby maintain­
ing the existing level of milk output within 
a protected market. Any ban would thus win 
favor from an organized political constitu­
ency while allowing government administra­
tors to claim they are championing public 
health, regardless of scientific testimony that 
little or no hazard existed.
The urgency to act grows once a haz­
ard has actually been demonstrated, even 
if the nature of the hazard is not yet fully 
understood, says Manolis Kogevinas, an epi­
demiologist with the Center for Research in 
Environmental Epidemiology in Barcelona. 
That has been the case in Europe, where the 
impact of bovine spongiform encephalo  pathy 
(BSE) continues to reverberate. As thousands 
of animals were diagnosed with this condi­
tion, politicians initially found themselves 
defending the safety of meat, offering assur­
ances that the best science of the day had 
found no implications for human health. 
Then, when further inquiry revealed that 
BSE was caused by a strange class of mis­
folded proteins called prions, many of these 
same politicians had to do a very public 
about­face, acknowledging that a link with 
human health might exist.
The BSE experience has unquestionably 
shaped the European outlook on environ­
mental health regulation, says Kogevinas. 
In particular, EU lawmakers have adopted 
a critical stance toward claims associated 
with the use of genetically modified organ­
isms (GMOs) in food and pharmaceutical 
processing. In 1998, this ongoing suspicion 
threatened to undermine an economic pil­
lar of Switzerland, where voters were offered 
the opportunity to all but outlaw genetic 
research on plants and animals within the 
country. The defeat of this referendum was 
a boon for Swiss­based drug giants such as 
Novartis and Hoffmann­La Roche, which 
depend heavily on their ability to engage 
in this kind of research. Had this measure 
passed, such work and the people conducting 
it likely would have migrated elsewhere, hol­
lowing out a mainstay of the Swiss economy. 
Nor did this 1998 decision put the mat­
ter to rest. In 2005 another referendum 
successfully installed a five­year morato­
rium on the use of GMO products in Swiss 
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agriculture. Although this latest decision 
does not have a direct impact on labora­
tory work, organizations such as the Swiss 
Biotech Association and Swiss Trade Asso­
ciation have voiced their fears that such leg­
islative maneuvers will restrict the freedom 
of researchers, fostering an international 
perception of their nation as one that is 
unfriendly to scientific activity.
Kogevinas concedes that the hue and cry 
over GMOs has no counterpart in North 
America. He suggests that this distinction 
reflects a more fundamental difference in 
the nature of public engagement, particu­
larly the manner in which administrative 
procedures are executed. “In North Amer­
ica you have a much more structured and 
transparent system for contact with institu­
tions, with organizations, with communi­
ties,” he says. “We have less of a tradition 
of that in Europe.” In fact, new rules have 
opened up EU regulatory review committee 
meetings that formerly provided little or no 
public access. 
Still, says Kogevinas, having long been 
excluded from such proceedings, many 
members of the scientific community have 
little appetite for contributing to the devel­
opment of public policy except in the most 
technical manner. That reluctance can play 
into the strategies adopted by many policy 
makers, as Kogevinas discovered when he 
waded into Spanish deliberations over the 
approval of municipal garbage incinerators, 
a potential source of dioxin emissions.
“The government asks certain questions 
as if they were scientific questions, when 
actually they are political questions, and 
sometimes we mix things up and try to 
respond to political questions using strictly 
scientific criteria,” he explains. The real 
question, he says, is not whether dioxin 
emissions should be limited to 0.1 ng/m3 or 
some other value. Instead, he says, “the real 
question is ‘What do we do with all the resi­
dues?’ The real question is whether we need 
a particular incinerator—or incinerators in 
general—as a means of waste reduction.”
Precautionary Tales
Similar distractions crop up in U.S. discus­
sions, whether the participants are looking 
at incinerators, stem cells, or GMOs. What 
often sets European conclusions apart, 
however, is commitment to a tenet known 
as the precautionary principle.
The precautionary principle—another 
way of saying “better safe than sorry”—has 
been making its way into the regulatory 
practices of governments since the 1930s. 
By the 1990s, major events such as the Rio 
de Janeiro Earth Summit began casting the 
idea in legal language. In 1998, the Sci­
ence and Environmental Health Network 
convened an international gathering of sci­
entists, philosophers, lawyers, and environ­
mental activists at the Johnson Foundation 
Wingspread Conference Center in Wiscon­
sin, yielding this succinct definition of the 
principle: “When an activity raises threats of 
harm to the environment or human health, 
precautionary measures should be taken 
even if some cause­and­effect relationships 
are not fully established scientifically.”
Members of the European Union took 
note, and within two years had adopted a 
similar statement as the foundation for EU 
environmental regulation. The result has 
imposed the juridical equivalent of “guilty 
until proven innocent” on any manu­
facturer seeking permission to introduce a 
product into the marketplace, demanding 
that public protection from potential harm 
be placed ahead of commercial interests.
Such a requirement accounts for much 
of the administrative distance that separates 
Europe from the United States, according 
to John Bucher, associate director of the 
National Toxicology Program (NTP), a 
multiagency toxicology and testing pro­
gram housed at the National Institute of 
Environmental Health Sciences. “The U.S. 
system has evolved around the supposition 
that the government is responsible for pro­
viding information, or utilizing and acting 
on information supplied by industry, that 
would suggest that a particular chemical 
shouldn’t be used in commerce,” he says. 
In other words, precaution is not imposed 
upon commercial interests as a default posi­
tion; instead, hazards and risks are defined 
by government on a case­by­case basis. 
Bucher suggests that although regulato­
ry agencies evaluate the risks of agents fairly 
uniformly, they may pay more attention to 
cases that rise to political or social promi­
nence. Nor can he and his colleagues in the 
NTP sway this tendency, since they lack 
the mandate of a regulatory agency and 
cannot define or assess risk as part of their 
observations. “So we must couch things in 
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terms of whether we have concerns over a 
particular level of human exposure that’s 
going on in the population,” he says. “We 
do however, select agents for evaluation 
through our programs . . . that we feel war­
rant regulatory agency consideration.”
The precautionary approach in the Unit­
ed States has been further stalled by a mod­
est rider added to a congressional spending 
bill in 2001—two sentences with no official 
name but known alternately as the Infor­
mation Quality Act or the Data Quality 
Act. This seemingly minor legislation has 
become contentious for requiring federal 
agencies to optimize the “quality, objectiv­
ity, utility, and integrity” of the information 
supporting regulatory activities.
Critics have highlighted this stipulation 
as a loophole for corporations to hold up 
the implementation of restrictions on their 
products. For Chris Mooney, author of the 
2005 book The Republican War on Science, 
this move represented “an unprecedented and 
cumbersome process by which government 
agencies must field complaints over the data, 
studies, and reports they release to the public. 
It is a science abuser’s dream come true.”
On the other hand, when the EPA consid­
ered the endocrine­disrupting potential of the 
herbicide atrazine in 2003, the Data Quality 
Act was invoked to clarify the experimental 
methods that were being used to argue that 
such effects from this agent had been observed 
in frogs. “Publication of a research article in a 
peer­reviewed scientific journal does not mean 
that the research has been accepted as valid by 
the scientific community and that it should be 
considered reliable for regulatory purposes,” 
argued members of the Center for Regula­
tory Effectiveness (CRE) in correspondence 
published in the January 2004 issue of EHP. 
A self­styled regulatory watchdog, the CRE 
applauded the introduction of the legislation 
as a brake against an overzealous embrace of 
preliminary or incomplete research findings.
That said, the precautionary principle is 
not altogether absent from U.S. regulations. 
In 2000, the FDA submitted a paper on its 
national food safety system to the Organisa­
tion for Economic Co­operation and Devel­
opment, complete with an annex illustrating 
the role that precaution plays in the system. 
This document outlined various adjustment 
factors that would be applied to account for 
prospects such as sensitive subgroups within 
a tested population, extrapolation from short­
term study data to assess chronic effects, 
extrapolation from animal data to human 
application, and variations within a human 
population, such as age or sex.
Still, the enforcement of precaution can 
raise new challenges that scientists do not yet 
know how to meet. Early in 2009, the Euro­
pean Parliament was putting the finishing 
touches on regulations banning chemicals 
that go into some of the world’s most widely 
used pesticides. Richard Tren, director of 
the nonprofit organization Africa Fighting 
Malaria, insists that the ban will prompt 
many nations on that continent to abandon 
their use of pesticides that are effectively and 
safely managing a public health scourge. 
“This is a victory for the environmen­
tal lobby and a defeat of sound science,” he 
wrote in the 20 January 2009 edition of the 
Vancouver newspaper The Province. “Sensible 
regulations should evaluate the risks posed 
by chemicals to humans and the environ­
ment based on sound scientific evidence. 
Regulators shouldn’t be solely concerned with 
whether a pesticide is hazardous in the lab. 
Most important is how the pesticide is used 
and how diluted the active ingredient is.” 
Observers such as McElgunn take another 
view. “Dilution of toxicants is not a solution, 
even when all the science is in and we have a 
NOAEL for sensitive end points,” she says. 
“Others would argue that sound scientific 
evidence should include both low­dose testing 
to uncover endocrine effects and neurodevel­
opmental effects, and cumulative assessments 
of substances that have similar properties or 
that produce similar adverse effects.”
For her part, Rachel Carson did not dis­
miss the use of chemical products, only their 
indiscriminate use—and she charged policy 
makers with the responsibility to discrimi­
nate. But weighing the scientific evidence in 
fulfillment of that responsibility is no simple 
task. According to Sarewitz, policy makers 
must deal with the harsh reality that there is 
not always one best way to use chemical com­
pounds, which is why it can be so difficult 
to identify and eliminate toxicants. “We’re 
very glib about how easy that task is,” he says, 
“both in terms of the question of identifying 
what things do and the costs and consequenc­
es of getting rid of stuff.”
Tim Lougheed 
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